Eylea is in its fifth year
Regeneron’s (REGN) flagship product, Eylea (Aflibercept), was launched in the US in November 2011. In the first half of 2016, Eylea earned $1.6 billion. To understand how Regeneron expanded Eylea’s various labels during these five years, you can read, Worst-Case Scenario for Regeneron: What If Eylea Sales Slow Down by 2018?
Will combination therapy make Eylea better?
Regeneron hasn’t increased the price for Eylea in the past five years. To maintain Eylea’s dominance in the DME (diabetic macular edema) space, REGN is looking for ways to improve the drug. REGN is conducting a phase two clinical trial that combines Eylea with the PDGF (platelet-derived growth factor) antibody. The phase two top-line data on the trial is expected by the end of 2016. If the PDGF inhibitor class offers benefits over VEGF (vascular endothelial growth factor) inhibitors, Regeneron will have an advantage over its competitors, as the single co-formulated injection will prove to be a major competitive advantage for the drug in the retinal space.
REGN is conducting two phase two clinical trials combining Eylea with Ang2 for the indication of AMD (age-related macular degeneration) and DME (diabetic macular edema). Regeneron competes with Novartis (NVS), Pfizer (PFE), and Roche Holdings (RHHBY) in the eye therapy space. To learn about how AMD treatments have evolved and Eylea’s competitors, please refer to Eylea Could Help Regeneron Focus on the Eye Therapy Segment.
If you want exposure to Regeneron but also want to reduce direct company-specific risk, you can invest in the First Trust NYSE Arca Biotechnology Index Fund (FBT). The fund holds 3.3% of its total holdings in Regeneron.
Continue to the next part for details on Regeneron’s agreement with Teva.